Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

English (EN)·Polski (PL)·Ukraiński (UK)
Przejdź do strony domowej biblioteki Uniwersytet Ekonomiczny we Wrocławiu Link otwiera się w nowym oknie Logo biblioteki Prolib Integro - strona głównaUniwersytet Ekonomiczny we Wrocławiu

Wyszukujesz frazę ""Irinotecan"" wg kryterium: Temat

  Lista filtrów
Wyrównaj
Wyświetlanie 1-20 z 492
Tytuł:
A randomised, double-blind, placebo-controlled multi-centre phase III trial of XELIRI/FOLFIRI plus simvastatin for patients with metastatic colorectal cancer.
Autorzy:
Lim SH; Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.
Kim TW; Division of Hematology-Oncology, Department of Medicine, Asan Medical Center, Seoul, South Korea.
Hong YS; Division of Hematology-Oncology, Department of Medicine, Asan Medical Center, Seoul, South Korea.
Han SW; Division of Hematology-Oncology, Department of Medicine, Seoul National University Hospital, Seoul, South Korea.
Lee KH; Division of Hematology-Oncology, Department of Medicine, Seoul National University Hospital, Seoul, South Korea.
Kang HJ; Division of Hematology-Oncology, Department of Medicine, Korea Cancer Center Hospital, Seoul, South Korea.
Hwang IG; Division of Hematology-Oncology, Department of Medicine, Chungang University Hospital, Seoul, South Korea.
Lee JY; Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.
Kim HS; Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.
Kim ST; Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.
Lee J; Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.
Park JO; Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.
Park SH; Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.
Park YS; Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.
Lim HY; Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.
Jung SH; Department of Biostatistics and Bioinformatics, Duke University, Durham, NC, USA.; Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.
Kang WK; Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.
Pokaż więcej
Źródło:
British journal of cancer [Br J Cancer] 2015 Nov 17; Vol. 113 (10), pp. 1421-6. Date of Electronic Publication: 2015 Oct 27.
Typ publikacji:
Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial
MeSH Terms:
Antineoplastic Combined Chemotherapy Protocols/*administration & dosage
Colorectal Neoplasms/*drug therapy
Hydroxymethylglutaryl-CoA Reductase Inhibitors/*administration & dosage
Simvastatin/*administration & dosage
Adult ; Aged ; Aged, 80 and over ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Camptothecin/administration & dosage ; Camptothecin/analogs & derivatives ; Camptothecin/therapeutic use ; Capecitabine/administration & dosage ; Capecitabine/therapeutic use ; Double-Blind Method ; Drug Administration Schedule ; Female ; Fluorouracil/administration & dosage ; Fluorouracil/therapeutic use ; Humans ; Hydroxymethylglutaryl-CoA Reductase Inhibitors/adverse effects ; Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use ; Irinotecan ; Leucovorin/administration & dosage ; Leucovorin/therapeutic use ; Male ; Middle Aged ; Neoplasm Metastasis ; Republic of Korea ; Simvastatin/adverse effects ; Simvastatin/therapeutic use ; Survival Analysis ; Treatment Outcome
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Pathological responses after angiogenesis or EGFR inhibitors in metastatic colorectal cancer depend on the chemotherapy backbone.
Autorzy:
Carrasco J; Department of Medical Oncology, Grand Hôpital de Charleroi (GHdC), Grand rue 3, 6000 Charleroi, Belgium.
Gizzi M; Department of Medical Oncology, Grand Hôpital de Charleroi (GHdC), Grand rue 3, 6000 Charleroi, Belgium.
Pairet G; Department of Pathology, Cliniques Universitaires St-Luc/Université Catholique de Louvain (UCL), Avenue Hippocrate 10, 1200 Brussels, Belgium.
Lannoy V; Department of Medical Oncology, Cliniques Universitaires St-Luc/Université Catholique de Louvain (UCL), Avenue Hippocrate 10, 1200 Brussels, Belgium.
Lefesvre P; Department of Molecular Pathology, Institut de Pathologie et de Génétique (IPG), Avenue Georges Lemaître 25, 6041 Gosselies, Belgium.
Gigot JF; Department of Abdominal Surgery and Transplantation, Cliniques Universitaires St-Luc/Université Catholique de Louvain (UCL), Avenue Hippocrate 10, 1200 Brussels, Belgium.
Hubert C; Department of Abdominal Surgery and Transplantation, Cliniques Universitaires St-Luc/Université Catholique de Louvain (UCL), Avenue Hippocrate 10, 1200 Brussels, Belgium.
Jouret-Mourin A; Department of Pathology, Cliniques Universitaires St-Luc/Université Catholique de Louvain (UCL), Avenue Hippocrate 10, 1200 Brussels, Belgium.
Humblet Y; Department of Medical Oncology, Cliniques Universitaires St-Luc/Université Catholique de Louvain (UCL), Avenue Hippocrate 10, 1200 Brussels, Belgium.
Canon JL; Department of Medical Oncology, Grand Hôpital de Charleroi (GHdC), Grand rue 3, 6000 Charleroi, Belgium.
Sempoux C; Department of Pathology, Cliniques Universitaires St-Luc/Université Catholique de Louvain (UCL), Avenue Hippocrate 10, 1200 Brussels, Belgium.
Chapaux X; Department of Radiolgy, Grand Hôpital de Charleroi (GHdC), Grand rue 3, 6000 Charleroi, Belgium.
Danse E; Department of Radiology, Cliniques Universitaires St-Luc/Université Catholique de Louvain (UCL), Avenue Hippocrate 10, 1200 Brussels, Belgium.
Tinton N; Department of Abdominal Surgery, Grand Hôpital de Charleroi (GHdC), Grand rue 3, 6000 Charleroi, Belgium.
Navez B; Department of Abdominal Surgery and Transplantation, Cliniques Universitaires St-Luc/Université Catholique de Louvain (UCL), Avenue Hippocrate 10, 1200 Brussels, Belgium.
Van den Eynde M; Department of Medical Oncology, Cliniques Universitaires St-Luc/Université Catholique de Louvain (UCL), Avenue Hippocrate 10, 1200 Brussels, Belgium.
Pokaż więcej
Źródło:
British journal of cancer [Br J Cancer] 2015 Nov 03; Vol. 113 (9), pp. 1298-304. Date of Electronic Publication: 2015 Oct 13.
Typ publikacji:
Journal Article
MeSH Terms:
Antineoplastic Agents/*therapeutic use
Colorectal Neoplasms/*drug therapy
Colorectal Neoplasms/*metabolism
Colorectal Neoplasms/*pathology
ErbB Receptors/*agonists
Neovascularization, Pathologic/*drug therapy
Adult ; Aged ; Aged, 80 and over ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Camptothecin/analogs & derivatives ; Camptothecin/therapeutic use ; Disease-Free Survival ; Female ; Humans ; Irinotecan ; Male ; Middle Aged ; Neovascularization, Pathologic/metabolism ; Neovascularization, Pathologic/pathology ; Organoplatinum Compounds/therapeutic use ; Oxaliplatin ; Retrospective Studies
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Upfront FOLFOXIRI+bevacizumab followed by fluoropyrimidin and bevacizumab maintenance in patients with molecularly unselected metastatic colorectal cancer.
Autorzy:
Stein A; University Medical Centre Hamburg-Eppendorf, Martinistrasse 52, Hamburg 20246, Germany.
Atanackovic D; University Medical Centre Hamburg-Eppendorf, Martinistrasse 52, Hamburg 20246, Germany.
Hildebrandt B; Charité Universitätsmedizin Berlin, Campus Charité Mitte, Charitéplatz 1, Berlin 10117, Germany.
Stübs P; University Hospital Magdeburg, Leipziger Strasse 44, Magdeburg 39120, Germany.
Brugger W; Schwarzwald-Baar Klinikum, Klinikstrasse 11, Villingen-Schwenningen 78052, Germany.
Hapke G; Marienkrankenhaus, Alfredstrasse 9, Hamburg 22087, Germany.
Steffens CC; MVZ Hämatologie/Onkologie Klinik Dr Hancken, Harsefelder Str. 8, Stade 21680, Germany.
Illerhaus G; Klinikum Stuttgart, Kriegsbergstraße 60, Stuttgart 70174, Germany.
Bluemner E; Ecron Acunova GmbH, Hahnstrasse 70, Frankfurt 60528, Germany.
Stöhlmacher J; Tumorgenetik Bonn, Maximilianstrasse 28d, Bonn 53111, Germany.
Bokemeyer C; University Medical Centre Hamburg-Eppendorf, Martinistrasse 52, Hamburg 20246, Germany.
Pokaż więcej
Źródło:
British journal of cancer [Br J Cancer] 2015 Sep 15; Vol. 113 (6), pp. 872-7. Date of Electronic Publication: 2015 Sep 03.
Typ publikacji:
Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
MeSH Terms:
Angiogenesis Inhibitors/*administration & dosage
Antineoplastic Combined Chemotherapy Protocols/*administration & dosage
Bevacizumab/*administration & dosage
Colorectal Neoplasms/*drug therapy
Adult ; Aged ; Angiogenesis Inhibitors/adverse effects ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Bevacizumab/adverse effects ; Camptothecin/administration & dosage ; Camptothecin/adverse effects ; Camptothecin/analogs & derivatives ; Colorectal Neoplasms/genetics ; Colorectal Neoplasms/mortality ; Disease-Free Survival ; Feasibility Studies ; Female ; Fluorouracil/administration & dosage ; Fluorouracil/adverse effects ; Genes, ras ; Humans ; Induction Chemotherapy/methods ; Irinotecan ; Leucovorin/administration & dosage ; Leucovorin/adverse effects ; Maintenance Chemotherapy/methods ; Male ; Middle Aged ; Organoplatinum Compounds/administration & dosage ; Organoplatinum Compounds/adverse effects ; Oxaliplatin ; Severity of Illness Index
SCR Protocol:
FOLFOXIRI protocol
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
An internally and externally validated nomogram for predicting the risk of irinotecan-induced severe neutropenia in advanced colorectal cancer patients.
Autorzy:
Ichikawa W; Division of Medical Oncology, Department of Medicine, Showa University, School of Medicine, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo 142-8555, Japan.
Uehara K; Division of Surgical Oncology, Department of Surgery, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya 466-8560, Japan.
Minamimura K; Department of Surgery, Mitsui Memorial Hospital, Kanda-Izumi-cho 1, Chiyoda-ku, Tokyo 101-8643, Japan.
Tanaka C; Department of Surgery, Gifu Prefectural General Medical Centre, 4-6-1 Noishiki, Gifu 500-8717, Japan.
Takii Y; Department of Surgery, Niigata Cancer Centre Hospital, 2-15-3 Kawagishi-cho, Chuo-ku, Niigata 951-8566, Japan.
Miyauchi H; Department of Frontier Surgery, Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuo-ku, Chiba 260-8670, Japan.
Sadahiro S; Department of Surgery, Tokai University, 143 Shimoyasuya, Isehara 259-1193, Japan.
Fujita K; Institute of Molecular Oncology, Showa University, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo 142-8555, Japan.
Moriwaki T; Division of Gastroenterology, University of Tsukuba, 1-1-1 Tennodai, Tsukuba 305-8575, Japan.
Nakamura M; Comprehensive Cancer Centre, Aizawa Hospital, 2-5-1 Honjo, Matsumoto 390-8510, Japan.
Takahashi T; Division of Medical Oncology, Department of Medicine, Showa University, School of Medicine, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo 142-8555, Japan.
Tsuji A; Department of Medical Oncology, Kobe City Medical Centre General Hospital, 2-1-1 Minatojimaminamimachi, Chuo-ku, Kobe 650-0047, Japan.
Shinozaki K; Division of Clinical Oncology, Hiroshima Prefectural Hospital, 1-5-54 Ujina-Kanda, Minami-ku, Hiroshima 734-8530, Japan.
Morita S; Department of Biomedical Statistics and Bioinformatics, Kyoto University Graduate School of Medicine, Yoshida-Konoe-cho, Sakyo-ku, Kyoto 606-8501, Japan.
Ando Y; Department of Clinical Oncology and Chemotherapy, Nagoya University Hospital, 65 Tsurumai-cho, Showa-ku, Nagoya 466-8560, Japan.
Okutani Y; Medical Affairs Department, Daiichi Sankyo, 3-5-1 Nihonbashi-Honcho, Chuo-ku 103-8426, Tokyo, Japan.
Sugihara M; Clinical Data & Biostatistics Department, Daiichi Sankyo, 1-2-58 Hiromachi, Shinagawa-ku, Tokyo 140-8710, Japan.
Sugiyama T; Department of Obstetrics and Gynaecology, Iwate Medical University School of Medicine, 19-1 Uchimaru, Morioka 020-8505, Japan.
Ohashi Y; Department of Integrated Science and Engineering for Sustainable Society, Faculty of Science and Engineering, Chuo University, 1-13-27 Kasuga, Tokyo 112-8551, Japan.
Sakata Y; CEO, Misawa City Hospital, 164-65, Aza Horiguchi, Oaza Misawa, Misawa, Aomori 033-0022, Japan.
Pokaż więcej
Źródło:
British journal of cancer [Br J Cancer] 2015 May 12; Vol. 112 (10), pp. 1709-16. Date of Electronic Publication: 2015 Apr 16.
Typ publikacji:
Journal Article; Multicenter Study; Observational Study; Research Support, Non-U.S. Gov't
MeSH Terms:
Nomograms*
Camptothecin/*analogs & derivatives
Colorectal Neoplasms/*drug therapy
Colorectal Neoplasms/*genetics
Neutropenia/*chemically induced
Neutropenia/*genetics
Aged ; Alleles ; Asian People/genetics ; Bilirubin/metabolism ; Camptothecin/administration & dosage ; Camptothecin/adverse effects ; Colorectal Neoplasms/metabolism ; Colorectal Neoplasms/pathology ; Female ; Genetic Predisposition to Disease ; Genotype ; Glucuronosyltransferase/genetics ; Humans ; Irinotecan ; Male ; Middle Aged ; Neutropenia/metabolism ; Neutropenia/pathology ; Neutrophils/metabolism ; Neutrophils/pathology ; Prospective Studies
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Sorafenib and irinotecan (NEXIRI) as second- or later-line treatment for patients with metastatic colorectal cancer and KRAS-mutated tumours: a multicentre Phase I/II trial.
Autorzy:
Samalin, E
Bouché, O
Thézenas, S
Francois, E
Adenis, A
Bennouna, J
Taieb, J
Desseigne, F
Seitz, J F
Conroy, T
Galais, M P
Assenat, E
Crapez, E
Poujol, S
Bibeau, F
Boissière, F
Laurent-Puig, P
Ychou, M
Mazard, T
Pokaż więcej
Źródło:
British Journal of Cancer. 3/4/2014, Vol. 110 Issue 5, p1148-1154. 7p. 1 Diagram, 4 Charts, 1 Graph.
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Diffusion-weighted MRI for imaging cell death after cytotoxic or apoptosis-inducing therapy.
Autorzy:
Papaevangelou E; Cancer Research UK Cancer Imaging Centre, Division of Radiotherapy and Imaging, The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, 15 Cotswold Road, Belmont, Sutton, Surrey SM2 5NG, UK.
Almeida GS; Cancer Research UK Cancer Imaging Centre, Division of Radiotherapy and Imaging, The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, 15 Cotswold Road, Belmont, Sutton, Surrey SM2 5NG, UK.
Jamin Y; Cancer Research UK Cancer Imaging Centre, Division of Radiotherapy and Imaging, The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, 15 Cotswold Road, Belmont, Sutton, Surrey SM2 5NG, UK.
Robinson SP; Cancer Research UK Cancer Imaging Centre, Division of Radiotherapy and Imaging, The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, 15 Cotswold Road, Belmont, Sutton, Surrey SM2 5NG, UK.
deSouza NM; Cancer Research UK Cancer Imaging Centre, Division of Radiotherapy and Imaging, The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, 15 Cotswold Road, Belmont, Sutton, Surrey SM2 5NG, UK.
Pokaż więcej
Źródło:
British journal of cancer [Br J Cancer] 2015 Apr 28; Vol. 112 (9), pp. 1471-9. Date of Electronic Publication: 2015 Apr 16.
Typ publikacji:
Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Adenocarcinoma/*secondary
Antineoplastic Agents, Phytogenic/*pharmacology
Apoptosis/*drug effects
Camptothecin/*analogs & derivatives
Colorectal Neoplasms/*pathology
Diffusion Magnetic Resonance Imaging/*methods
Dipeptides/*pharmacology
Indoles/*pharmacology
Adenocarcinoma/drug therapy ; Adenocarcinoma/metabolism ; Animals ; Blotting, Western ; Camptothecin/pharmacology ; Cell Proliferation/drug effects ; Colorectal Neoplasms/drug therapy ; Colorectal Neoplasms/metabolism ; Female ; Humans ; Immunoenzyme Techniques ; Irinotecan ; Lymphatic Metastasis ; Mice ; Mice, Nude ; Necrosis ; Tumor Cells, Cultured ; Xenograft Model Antitumor Assays
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
OATP1B1 and tumour OATP1B3 modulate exposure, toxicity, and survival after irinotecan-based chemotherapy.
Autorzy:
Teft WA; Department of Medicine, Division of Clinical Pharmacology, London Health Sciences Centre-University Hospital, Western University, Room B9-132, 339 Windermere Road, London, Ontario, Canada N6A 5A5.
Welch S; Department of Oncology, London Health Sciences Centre-Victoria Hospital, Western University, 800 Commissioners Road East, PO Box 5010, London, Ontario, Canada N6A 5W9.
Lenehan J; Department of Oncology, London Health Sciences Centre-Victoria Hospital, Western University, 800 Commissioners Road East, PO Box 5010, London, Ontario, Canada N6A 5W9.
Parfitt J; Department of Pathology, London Health Sciences Centre - University Hospital, Western University, 339 Windermere Road, London, Ontario, Canada N6A 5A5.
Choi YH; Department of Epidemiology and Biostatistics, Kresge Building, Western University, London Ontario, Canada N6A 5C1.
Winquist E; Department of Oncology, London Health Sciences Centre-Victoria Hospital, Western University, 800 Commissioners Road East, PO Box 5010, London, Ontario, Canada N6A 5W9.
Kim RB; 1] Department of Medicine, Division of Clinical Pharmacology, London Health Sciences Centre-University Hospital, Western University, Room B9-132, 339 Windermere Road, London, Ontario, Canada N6A 5A5 [2] Department of Oncology, London Health Sciences Centre-Victoria Hospital, Western University, 800 Commissioners Road East, PO Box 5010, London, Ontario, Canada N6A 5W9 [3] Department of Physiology and Pharmacology, Medical Sciences Building, Western University, London, Ontario, Canada N6A 5C1.
Pokaż więcej
Źródło:
British journal of cancer [Br J Cancer] 2015 Mar 03; Vol. 112 (5), pp. 857-65. Date of Electronic Publication: 2015 Jan 22.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Antineoplastic Agents, Phytogenic/*pharmacokinetics
Camptothecin/*analogs & derivatives
Colorectal Neoplasms/*drug therapy
Multidrug Resistance-Associated Proteins/*genetics
Organic Anion Transporters/*genetics
Organic Anion Transporters, Sodium-Independent/*genetics
Adult ; Aged ; Aged, 80 and over ; Antineoplastic Agents, Phytogenic/adverse effects ; Antineoplastic Agents, Phytogenic/therapeutic use ; Camptothecin/adverse effects ; Camptothecin/pharmacokinetics ; Camptothecin/therapeutic use ; Colorectal Neoplasms/genetics ; Colorectal Neoplasms/pathology ; Disease-Free Survival ; Female ; Humans ; Irinotecan ; Liver-Specific Organic Anion Transporter 1 ; Male ; Middle Aged ; Multidrug Resistance-Associated Protein 2 ; Polymorphism, Single Nucleotide ; Solute Carrier Organic Anion Transporter Family Member 1B3
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
A triplet combination with irinotecan (CPT-11), oxaliplatin (LOHP), continuous infusion 5-fluorouracil and leucovorin (FOLFOXIRI) plus cetuximab as first-line treatment in KRAS wt, metastatic colorectal cancer: a pilot phase II trial.
Autorzy:
Saridaki, Z
Androulakis, N
Vardakis, N
Vamvakas, L
Kabouraki, E
Kalbakis, K
Hatzidaki, D
Voutsina, A
Mavroudis, D
Georgoulias, V
Souglakos, J
Pokaż więcej
Źródło:
British Journal of Cancer. 12/4/2012, Vol. 107 Issue 12, p1932-1937. 6p. 4 Charts.
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Shed Syndecan-1 is involved in chemotherapy resistance via the EGFR pathway in colorectal cancer.
Autorzy:
Wang X; Key Laboratory of Cancer Prevention and Therapy, Department of Gastrointestinal Oncology, National Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin 300060, China.
Zuo D; Key Laboratory of Cancer Prevention and Therapy, Department of Clinical Laboratory, National Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin 300060, China.
Chen Y; Guangdong Provincial Key Laboratory of Gastroenterology, Department of Digestive Diseases, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China.
Li W; Department of Cardiovascular Medicine, Tianjin Chest Hospital, Tianjin 300000, China.
Liu R; Key Laboratory of Cancer Prevention and Therapy, Department of Gastrointestinal Oncology, National Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin 300060, China.
He Y; Department of Hepatology and Infectious Disease, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China.
Ren L; Key Laboratory of Cancer Prevention and Therapy, Department of Clinical Laboratory, National Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin 300060, China.
Zhou L; Key Laboratory of Cancer Prevention and Therapy, Department of Gastrointestinal Oncology, National Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin 300060, China.
Deng T; Key Laboratory of Cancer Prevention and Therapy, Department of Gastrointestinal Oncology, National Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin 300060, China.
Wang X; Guangdong Provincial Key Laboratory of Gastroenterology, Department of Digestive Diseases, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China.
Ying G; Laboratory of Cancer Cell Biology, Key Laboratory of Cancer Prevention and Therapy, National Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin 300060, China.
Ba Y; Key Laboratory of Cancer Prevention and Therapy, Department of Gastrointestinal Oncology, National Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin 300060, China.
Pokaż więcej
Źródło:
British journal of cancer [Br J Cancer] 2014 Nov 11; Vol. 111 (10), pp. 1965-76. Date of Electronic Publication: 2014 Oct 16.
Typ publikacji:
Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Drug Resistance, Neoplasm*
Antineoplastic Combined Chemotherapy Protocols/*pharmacology
Colorectal Neoplasms/*metabolism
ErbB Receptors/*metabolism
Syndecan-1/*metabolism
Aged ; Apoptosis/drug effects ; Biomarkers, Tumor/metabolism ; Blotting, Western ; Camptothecin/administration & dosage ; Camptothecin/analogs & derivatives ; Case-Control Studies ; Cell Proliferation/drug effects ; Cisplatin/administration & dosage ; Colorectal Neoplasms/drug therapy ; Colorectal Neoplasms/pathology ; Female ; Flow Cytometry ; Fluorescent Antibody Technique ; Fluorouracil/administration & dosage ; Humans ; Immunoenzyme Techniques ; Irinotecan ; Male ; Matrix Metalloproteinase 7/metabolism ; Neoplasm Grading ; Neoplasm Invasiveness ; Neoplasm Staging ; Organoplatinum Compounds/administration & dosage ; Oxaliplatin ; Paclitaxel/administration & dosage ; RNA, Messenger/genetics ; RNA, Small Interfering/genetics ; Real-Time Polymerase Chain Reaction ; Reverse Transcriptase Polymerase Chain Reaction ; Syndecan-1/antagonists & inhibitors ; Syndecan-1/genetics ; Tumor Cells, Cultured
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Prognostic significance of AMPK activation in advanced stage colorectal cancer treated with chemotherapy plus bevacizumab.
Autorzy:
Zulato E; Immunology and Molecular Oncology Unit, Istituto Oncologico Veneto-IRCCS, Via Gattamelata 64, 35138 Padova, Italy.
Bergamo F; Medical Oncology 1 Unit, Istituto Oncologico Veneto-IRCCS, Via Gattamelata 64, 35138 Padova, Italy.
De Paoli A; Clinical Trials and Biostatistics Unit, Istituto Oncologico Veneto-IRCCS, Via Gattamelata 64, 35138 Padova, Italy.
Griguolo G; Medical Oncology 1 Unit, Istituto Oncologico Veneto-IRCCS, Via Gattamelata 64, 35138 Padova, Italy.
Esposito G; Immunology and Molecular Oncology Unit, Istituto Oncologico Veneto-IRCCS, Via Gattamelata 64, 35138 Padova, Italy.
De Salvo GL; Clinical Trials and Biostatistics Unit, Istituto Oncologico Veneto-IRCCS, Via Gattamelata 64, 35138 Padova, Italy.
Mescoli C; Pathology and Cytopathology Unit, Department of Medicine, University of Padova, Via Gabelli 61, 35121 Padova, Italy.
Rugge M; Pathology and Cytopathology Unit, Department of Medicine, University of Padova, Via Gabelli 61, 35121 Padova, Italy.
Nardin M; Radiology Unit, Istituto Oncologico Veneto-IRCCS, Via Gattamelata 64, 35138 Padova, Italy.
Di Grazia L; Radiology Unit, Istituto Oncologico Veneto-IRCCS, Via Gattamelata 64, 35138 Padova, Italy.
Lonardi S; Medical Oncology 1 Unit, Istituto Oncologico Veneto-IRCCS, Via Gattamelata 64, 35138 Padova, Italy.
Indraccolo S; Immunology and Molecular Oncology Unit, Istituto Oncologico Veneto-IRCCS, Via Gattamelata 64, 35138 Padova, Italy.
Zagonel V; Medical Oncology 1 Unit, Istituto Oncologico Veneto-IRCCS, Via Gattamelata 64, 35138 Padova, Italy.
Pokaż więcej
Źródło:
British journal of cancer [Br J Cancer] 2014 Jul 08; Vol. 111 (1), pp. 25-32. Date of Electronic Publication: 2014 Jun 03.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
AMP-Activated Protein Kinases/*metabolism
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Colorectal Neoplasms/*drug therapy
Colorectal Neoplasms/*enzymology
Adult ; Aged ; Angiogenesis Inhibitors/administration & dosage ; Antibodies, Monoclonal, Humanized/administration & dosage ; Bevacizumab ; Biomarkers, Tumor/metabolism ; Camptothecin/administration & dosage ; Camptothecin/analogs & derivatives ; Enzyme Activation ; Female ; Fluorouracil/administration & dosage ; Humans ; Immunohistochemistry ; Irinotecan ; Male ; Middle Aged ; Prognosis
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Se-methylselenocysteine offers selective protection against toxicity and potentiates the antitumour activity of anticancer drugs in preclinical animal models.
Autorzy:
Cao S; Department of Medicine, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY 14263, USA.
Durrani FA; Department of Cancer Biology, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY 14263, USA.
Tóth K; Department of Cancer Biology, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY 14263, USA.
Rustum YM; Department of Cancer Biology, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY 14263, USA.
Pokaż więcej
Źródło:
British journal of cancer [Br J Cancer] 2014 Apr 02; Vol. 110 (7), pp. 1733-43. Date of Electronic Publication: 2014 Mar 11.
Typ publikacji:
Journal Article; Research Support, N.I.H., Extramural
MeSH Terms:
Cytoprotection*
Antineoplastic Combined Chemotherapy Protocols/*adverse effects
Neoplasms/*drug therapy
Selenocysteine/*analogs & derivatives
Animals ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Camptothecin/administration & dosage ; Camptothecin/adverse effects ; Camptothecin/analogs & derivatives ; Cisplatin/administration & dosage ; Cisplatin/adverse effects ; Cyclophosphamide/administration & dosage ; Cyclophosphamide/adverse effects ; Female ; Humans ; Irinotecan ; Mice ; Mice, Nude ; Neoplasms/pathology ; Organoplatinum Compounds/administration & dosage ; Organoplatinum Compounds/adverse effects ; Oxaliplatin ; Rats ; Rats, Inbred F344 ; Selenocysteine/administration & dosage ; Tumor Cells, Cultured ; Xenograft Model Antitumor Assays
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
KRAS-mutated plasma DNA as predictor of outcome from irinotecan monotherapy in metastatic colorectal cancer.
Autorzy:
Spindler KG; 1] Department of Oncology, Vejle Hospital, Vejle, Denmark [2] Danish Colorectal Cancer Group South, Vejle Hospital, Kabbeltoft 25, 7100, Vejle, Denmark.
Appelt AL
Pallisgaard N
Andersen RF
Jakobsen A
Pokaż więcej
Źródło:
British journal of cancer [Br J Cancer] 2013 Dec 10; Vol. 109 (12), pp. 3067-72. Date of Electronic Publication: 2013 Nov 21.
Typ publikacji:
Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Antineoplastic Agents, Phytogenic/*therapeutic use
Camptothecin/*analogs & derivatives
Colorectal Neoplasms/*blood
Colorectal Neoplasms/*drug therapy
DNA, Neoplasm/*blood
Proto-Oncogene Proteins/*blood
Proto-Oncogene Proteins/*genetics
ras Proteins/*blood
ras Proteins/*genetics
Adult ; Aged ; Aged, 80 and over ; Camptothecin/therapeutic use ; Cohort Studies ; Colorectal Neoplasms/genetics ; Colorectal Neoplasms/pathology ; DNA, Neoplasm/genetics ; Disease-Free Survival ; Female ; Humans ; Irinotecan ; Male ; Middle Aged ; Mutation ; Neoplasm Metastasis ; Prognosis ; Prospective Studies ; Proto-Oncogene Proteins B-raf/blood ; Proto-Oncogene Proteins B-raf/genetics ; Proto-Oncogene Proteins p21(ras) ; Retrospective Studies ; Treatment Outcome
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
A c-Met inhibitor increases the chemosensitivity of cancer stem cells to the irinotecan in gastric carcinoma.
Autorzy:
Yashiro M; 1] Department of Surgical Oncology, Osaka City University Graduate School of Medicine, 1-4-3 Asahi-machi, Abeno-ku, Osaka 545-8585, Japan [2] Oncology Institute of Geriatrics and Medical Science, Osaka City University Graduate School of Medicine, 1-4-3 Asahi-machi, Abeno-ku, Osaka 545-8585, Japan.
Nishii T
Hasegawa T
Matsuzaki T
Morisaki T
Fukuoka T
Hirakawa K
Pokaż więcej
Źródło:
British journal of cancer [Br J Cancer] 2013 Nov 12; Vol. 109 (10), pp. 2619-28. Date of Electronic Publication: 2013 Oct 15.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Antineoplastic Agents, Phytogenic/*therapeutic use
Camptothecin/*analogs & derivatives
Neoplastic Stem Cells/*drug effects
Protein Kinase Inhibitors/*pharmacology
Proto-Oncogene Proteins c-met/*antagonists & inhibitors
Stomach Neoplasms/*drug therapy
Animals ; Antineoplastic Agents, Phytogenic/pharmacology ; Camptothecin/pharmacology ; Camptothecin/therapeutic use ; Drug Resistance, Neoplasm/drug effects ; Drug Synergism ; Humans ; Irinotecan ; Mice ; Mice, Inbred BALB C ; Mice, Nude ; Neoplastic Stem Cells/pathology ; Stomach Neoplasms/pathology ; Tumor Cells, Cultured ; Xenograft Model Antitumor Assays
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Evaluation of prognostic factors in liver-limited metastatic colorectal cancer: a preplanned analysis of the FIRE-1 trial.
Autorzy:
Giessen C; Department of Medical Oncology, Klinikum Grosshadern and Comprehensive Cancer Center, University of Munich, Marchioninistrasse 15, 81377 Munich, Germany.
Fischer von Weikersthal L
Laubender RP
Stintzing S
Modest DP
Schalhorn A
Schulz C
Heinemann V
Pokaż więcej
Źródło:
British journal of cancer [Br J Cancer] 2013 Sep 17; Vol. 109 (6), pp. 1428-36. Date of Electronic Publication: 2013 Aug 20.
Typ publikacji:
Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms:
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Colorectal Neoplasms/*drug therapy
Colorectal Neoplasms/*pathology
Liver Neoplasms/*drug therapy
Liver Neoplasms/*secondary
Adult ; Aged ; Camptothecin/administration & dosage ; Camptothecin/analogs & derivatives ; Disease-Free Survival ; Female ; Humans ; Irinotecan ; Liver Neoplasms/surgery ; Male ; Middle Aged ; Prognosis ; Proportional Hazards Models ; Survival Analysis ; Young Adult
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
A randomised, placebo-controlled, double-blind study of aprepitant in nondrinking women younger than 70 years receiving moderately emetogenic chemotherapy.
Autorzy:
Tanioka M; Medical Oncology, Hyogo Cancer Center, Akashi, Japan. />Kitao A
Matsumoto K
Shibata N
Yamaguchi S
Fujiwara K
Minami H
Katakami N
Morita S
Negoro S
Pokaż więcej
Źródło:
British journal of cancer [Br J Cancer] 2013 Aug 20; Vol. 109 (4), pp. 859-65. Date of Electronic Publication: 2013 Jul 16.
Typ publikacji:
Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms:
Temperance*
Antiemetics/*therapeutic use
Antineoplastic Combined Chemotherapy Protocols/*adverse effects
Morpholines/*therapeutic use
Neoplasms/*drug therapy
Vomiting/*prevention & control
Adult ; Aged ; Aprepitant ; Camptothecin/administration & dosage ; Camptothecin/adverse effects ; Camptothecin/analogs & derivatives ; Carboplatin/administration & dosage ; Carboplatin/adverse effects ; Dexamethasone/therapeutic use ; Double-Blind Method ; Drug Therapy, Combination ; Endometrial Neoplasms/drug therapy ; Female ; Granisetron/therapeutic use ; Humans ; Irinotecan ; Logistic Models ; Middle Aged ; Ovarian Neoplasms/drug therapy ; Treatment Outcome ; Vomiting/chemically induced ; Vomiting/drug therapy
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
A multinational phase 2 study of nanoliposomal irinotecan sucrosofate (PEP02, MM-398) for patients with gemcitabine-refractory metastatic pancreatic cancer.
Autorzy:
Ko AH; Division of Hematology/Oncology, Comprehensive Cancer Center, University of California, San Francisco, 1600 Divisadero Street, San Francisco, CA 94115, USA. />Tempero MA
Shan YS
Su WC
Lin YL
Dito E
Ong A
Wang YW
Yeh CG
Chen LT
Pokaż więcej
Źródło:
British journal of cancer [Br J Cancer] 2013 Aug 20; Vol. 109 (4), pp. 920-5. Date of Electronic Publication: 2013 Jul 23.
Typ publikacji:
Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
MeSH Terms:
Adenocarcinoma/*drug therapy
Antineoplastic Agents/*therapeutic use
Camptothecin/*analogs & derivatives
Pancreatic Neoplasms/*drug therapy
Sucrose/*analogs & derivatives
Adenocarcinoma/pathology ; Adult ; Aged ; Aged, 80 and over ; Camptothecin/therapeutic use ; Disease-Free Survival ; Drug Combinations ; Female ; Humans ; Irinotecan ; Liposomes ; Male ; Middle Aged ; Pancreatic Neoplasms/pathology ; Salvage Therapy ; Sucrose/therapeutic use ; Treatment Outcome
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
A short-term colorectal cancer sphere culture as a relevant tool for human cancer biology investigation.
Autorzy:
Weiswald LB; IFR71 Sciences du Médicament, Faculté des Sciences Pharmaceutiques et Biologiques, Université Paris Descartes, Sorbonne Paris Cité, 4 Avenue de l'Observatoire, F-75006 Paris, France.
Richon S
Massonnet G
Guinebretière JM
Vacher S
Laurendeau I
Cottu P
Marangoni E
Nemati F
Validire P
Bellet D
Bièche I
Dangles-Marie V
Pokaż więcej
Źródło:
British journal of cancer [Br J Cancer] 2013 Apr 30; Vol. 108 (8), pp. 1720-31. Date of Electronic Publication: 2013 Mar 28.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Colorectal Neoplasms/*pathology
Animals ; Camptothecin/analogs & derivatives ; Camptothecin/pharmacology ; Cell Line, Tumor ; Cell Movement/physiology ; Cell Survival/physiology ; Colorectal Neoplasms/drug therapy ; Colorectal Neoplasms/genetics ; Drug Screening Assays, Antitumor ; Female ; Fluorouracil/pharmacology ; Humans ; Irinotecan ; Mice ; Mice, Nude ; Mice, SCID ; Microscopy, Confocal ; Neoplasm Transplantation ; Random Allocation ; Real-Time Polymerase Chain Reaction ; Spheroids, Cellular/pathology ; Transplantation, Heterologous ; Xenograft Model Antitumor Assays
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Wyświetlanie 1-20 z 492

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies